Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia

Peter C. Trask; David Cella; Nadine Besson; Virginia Kelly; Tamás Masszi; Dong Wook Kim

doi:10.1016/j.leukres.2011.10.011

Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia

Peter C. Trask^*, David Cella, Nadine Besson, Virginia Kelly, Tamás Masszi, Dong Wook Kim

^*Corresponding author for this work

Medical Social Sciences

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

Understanding the impact of second-line tyrosine kinase inhibitor therapy on the health-related quality of life (HRQOL) of imatinib (IM)-resistant and IM-intolerant chronic phase chronic myeloid leukemia (CP CML) patients is important given the increased survival that comes with therapy. As part of a bosutinib single-arm phase 2 trial, 200 IM-resistant and 88 IM-intolerant CP CML patients' HRQOL was assessed prior to and throughout treatment with the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Little HRQOL impairment was demonstrated at baseline. Over the course of 96. weeks on bosutinib therapy, patients noted statistically significant and/or clinically meaningful improvements on several FACT-Leu scales.

Original language	English (US)
Pages (from-to)	438-442
Number of pages	5
Journal	Leukemia Research
Volume	36
Issue number	4
DOIs	https://doi.org/10.1016/j.leukres.2011.10.011
State	Published - Apr 2012

Funding

Editorial support was provided by Kimberly Brooks, PhD, at a MedErgy HealthGroup company, and was funded by Pfizer .

Keywords

Bosutinib
Chronic myeloid leukemia
Chronic phase
FACT-Leu
Health-related quality of life

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2011.10.011

Cite this

@article{da483585540643518db835693a0bea91,

title = "Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia",

abstract = "Understanding the impact of second-line tyrosine kinase inhibitor therapy on the health-related quality of life (HRQOL) of imatinib (IM)-resistant and IM-intolerant chronic phase chronic myeloid leukemia (CP CML) patients is important given the increased survival that comes with therapy. As part of a bosutinib single-arm phase 2 trial, 200 IM-resistant and 88 IM-intolerant CP CML patients' HRQOL was assessed prior to and throughout treatment with the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Little HRQOL impairment was demonstrated at baseline. Over the course of 96. weeks on bosutinib therapy, patients noted statistically significant and/or clinically meaningful improvements on several FACT-Leu scales.",

keywords = "Bosutinib, Chronic myeloid leukemia, Chronic phase, FACT-Leu, Health-related quality of life",

author = "Trask, \{Peter C.\} and David Cella and Nadine Besson and Virginia Kelly and Tam{\'a}s Masszi and Kim, \{Dong Wook\}",

note = "Funding Information: Editorial support was provided by Kimberly Brooks, PhD, at a MedErgy HealthGroup company, and was funded by Pfizer . ",

year = "2012",

month = apr,

doi = "10.1016/j.leukres.2011.10.011",

language = "English (US)",

volume = "36",

pages = "438--442",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "4",

}

TY - JOUR

T1 - Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia

AU - Trask, Peter C.

AU - Cella, David

AU - Besson, Nadine

AU - Kelly, Virginia

AU - Masszi, Tamás

AU - Kim, Dong Wook

N1 - Funding Information: Editorial support was provided by Kimberly Brooks, PhD, at a MedErgy HealthGroup company, and was funded by Pfizer .

PY - 2012/4

Y1 - 2012/4

N2 - Understanding the impact of second-line tyrosine kinase inhibitor therapy on the health-related quality of life (HRQOL) of imatinib (IM)-resistant and IM-intolerant chronic phase chronic myeloid leukemia (CP CML) patients is important given the increased survival that comes with therapy. As part of a bosutinib single-arm phase 2 trial, 200 IM-resistant and 88 IM-intolerant CP CML patients' HRQOL was assessed prior to and throughout treatment with the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Little HRQOL impairment was demonstrated at baseline. Over the course of 96. weeks on bosutinib therapy, patients noted statistically significant and/or clinically meaningful improvements on several FACT-Leu scales.

AB - Understanding the impact of second-line tyrosine kinase inhibitor therapy on the health-related quality of life (HRQOL) of imatinib (IM)-resistant and IM-intolerant chronic phase chronic myeloid leukemia (CP CML) patients is important given the increased survival that comes with therapy. As part of a bosutinib single-arm phase 2 trial, 200 IM-resistant and 88 IM-intolerant CP CML patients' HRQOL was assessed prior to and throughout treatment with the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Little HRQOL impairment was demonstrated at baseline. Over the course of 96. weeks on bosutinib therapy, patients noted statistically significant and/or clinically meaningful improvements on several FACT-Leu scales.

KW - Bosutinib

KW - Chronic myeloid leukemia

KW - Chronic phase

KW - FACT-Leu

KW - Health-related quality of life

UR - http://www.scopus.com/inward/record.url?scp=84857234074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857234074&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.10.011

DO - 10.1016/j.leukres.2011.10.011

M3 - Article

C2 - 22036634

AN - SCOPUS:84857234074

SN - 0145-2126

VL - 36

SP - 438

EP - 442

JO - Leukemia Research

JF - Leukemia Research

IS - 4

ER -

Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this